Slide 1: CHAPTER-3 Topline Data
September 8, 2026 CHAPTER-3 Topline Data This presentation includes data for an investigational product not yet approved by regulatory authorities. Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-l
Slide 3: CHAPTER-3 topline presenters
Marc A. Riedl, M.D., M.S., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD); principal investigator in the CHAPTER-3 study CHAPTER-3 topline presenters Berndt Modig, Chief Executive Office
Slide 4: Strong momentum across ODT and LTP with key milestones ahead
Strong momentum across ODT and LTP with key milestones ahead Positive RAPIDe-1 Phase 2 Data Positive RAPIDe-3 Phase 3 Data U.S. NDA and EU MAA Accepted FDA PDUFA goal April 23, 2027 U.S. ODT Launch Positive CHAPTER-1 Phase 2 Data Positive CHAPTER-3 Phase 3 Data CREAATE Phase 3 Part 1 Data: 1Q2027 U.
Slide 5: CHAPTER-3 study design
CHAPTER-3 study design First pivotal trial in prophylaxis to include all types of HAE Screening Period (includes run-in period) R Deucrictibant XR 40 mg, once daily n=55 Placebo n=30 Open-Label Extension or End-of-Study Visit Treatment Period: 24 Weeks Participants aged 12 years and above HAE Type 1
Slide 6: Baseline demographics and disease characteristics
Baseline demographics and disease characteristics Placebo N = 30 Deucrictibant XR N = 55 Age – mean, median (IQR) 39.3, 43.0 (23.0-50.0) 38.6, 40.0 (29.0-47.0) ≥12–<18 years 4 (13.3%) 4 (7.3%) Sex – n (%): Female 22 (73.3%) 34 (61.8%) Race – n (%) White 24 (80.0%) 35 (63.6%) Asian 3 (10.0%) 13 (23.6
Slide 7: Deucrictibant XR reduced attack rate versus placebo
Deucrictibant XR reduced attack rate versus placebo Primary endpoint 83% reduction (95% CI: 72-90%) p<0.0001 87% reduction in HAE Type 1/2 subgroup (n=80)* This presentation includes data for an investigational product not yet approved by regulatory authorities. *Additional analysis of HAE Type 1/2,
Slide 8: Attack reduction achieved within one week and sustained throughout the study
This presentation includes data for an investigational product not yet approved by regulatory authorities. Notes: Results are descriptive and based on observed data. Points represent mean percentage change from baseline in attack rate; error bars indicate standard errors. Abbreviations: DEU XR: deuc
Slide 9: Robust reductions in attack rate from baseline with deucrictibant XR
Robust reductions in attack rate from baseline with deucrictibant XR All other secondary efficacy endpoints were achieved with statistically significant results This presentation includes data for an investigational product not yet approved by regulatory authorities. Notes: Attack rate = time-normal
Slide 10: Meaningful quality of life improvement with deucrictibant XR
Meaningful quality of life improvement with deucrictibant XR Change from baseline in AE-QoL total score Placebo Deucrictibant XR 40 mg Baseline Mean 51.74 51.33 Change from Baseline at Week 24 (LS Mean) -8.70 -32.23 Difference vs Placebo (95% CI) -23.53 (-32.15, -14.92) p <0.0001 This presentation i
Slide 11: Deucrictibant XR treatment was well tolerated
Deucrictibant XR treatment was well tolerated Treatment-Emergent Adverse Events (TEAEs) – n (%) Placebo (N=30) Deucrictibant XR (N=55) Any TEAEs 17 (56.7) 42 (76.4) Maximum Grade 1 6 (20.0) 15 (27.3) Maximum Grade 2 11 (36.7) 23 (41.8) Maximum Grade 3 0 3 (5.5) Maximum Grade 4 0 1 (1.8) Maximum Grad
Slide 12: Deucrictibant XR demonstrated meaningful attack rate reduction with well-tolerated safety profile
Deucrictibant XR demonstrated meaningful attack rate reduction vs placebo with a well-tolerated safety profile This presentation includes data for an investigational product not yet approved by regulatory authorities. All secondary efficacy endpoints met with statistical significance Early-onset pro
Slide 13: Aspire to become a bradykinin-mediated angioedema market leader
Aspire to become a bradykinin-mediated angioedema market leader ODT 1 Leverage B2R Platform ODT Market Leadership Deliver effective control of attacks with reduced treatment burden Expand across AE-BK and other bradykinin-mediated diseases to build a differentiated franchise One molecule. Multiple o
Slide 14: Near-term value drivers
Near-term value drivers Note: Dates are anticipated. Abbreviations: AAE-C1INH: acquired angioedema due to C1 inhibitor deficiency. HAE: hereditary angioedema. LTE: long-term extension. OLE: open-label extension. NDA: New Drug Application. PDUFA: Prescription Drug User Fee Act target date. Source: RA
Slide 15: www.pharvaris.com
NASDAQ: PHVS www.pharvaris.com